Efficacy of Oral Alendronate in Children With Osteogenesis Imperfecta

The purpose of this study was to investigate the efficacy of oral alendronate for children with osteogenesis imperfecta. Nine boys and seven girls of average age 9.5 years were given oral alendronate for an average of 4 years. Fracture frequency decreased, and in more than half of the patients the ambulatory/mobility status improved. Bone mineral density improved significantly, and restoration of collapsed vertebral bodies was observed. Urinary excretion of calcium and a bone resorption marker decreased significantly. Iliac crest physis biopsy showed an expanded primary spongiosa area with numerous multinucleated cells. This study reveals that oral alendronate caused biochemical, radiologic, and histologic changes along with clinical improvement. Oral alendronate treatment, which is convenient for the school-age group, was found to be a tolerable and efficacious treatment for children with moderate or severe osteogenesis imperfecta.

[1]  R. Engelbert,et al.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study , 2004, The Lancet.

[2]  F. Glorieux,et al.  Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. , 2003, Pediatrics.

[3]  A. Oberbauer,et al.  Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. , 2003, Bone.

[4]  A. Boskey,et al.  Alendronate Treatment for Infants with Osteogenesis Imperfecta: Demonstration of Efficacy in a Mouse Model , 2002, Pediatric Research.

[5]  F. Glorieux,et al.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. , 2002, The Journal of clinical investigation.

[6]  L. Root,et al.  A Controlled Study of the Effects of Alendronate in a Growing Mouse Model of Osteogenesis Imperfecta , 2001, Calcified Tissue International.

[7]  I Larzillière,et al.  [Esophagitis associated with the use of alendronate]. , 1999, Gastroenterologie clinique et biologique.

[8]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[9]  S. Söderhäll,et al.  Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta , 1998, Acta paediatrica.

[10]  G. Massa,et al.  Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate) , 1997, European Journal of Pediatrics.

[11]  R. Ball,et al.  Hypercalcaemia in osteogenesis imperfecta treated with pamidronate , 1997, Archives of disease in childhood.

[12]  J. Mucklow,et al.  Studies of the oral bioavailability of alendronate , 1995, Clinical pharmacology and therapeutics.

[13]  B. Maldague,et al.  Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta , 2004, Skeletal Radiology.

[14]  I. Fujiwara,et al.  Intravenous pamidronate treatment in osteogenesis imperfecta. , 1998, European journal of pediatrics.

[15]  J. Huaux,et al.  Is APD a promising drug in the treatment of severe osteogenesis imperfecta? , 1988, Journal of pediatric orthopedics.